Jump to navigation
This course was a live CME-certified Ancillary Symposium presented at ENDO 2019 (March 23, 2019), held in New Orleans, LA. This educational activity is supported by an independent medical educational grant from Ultragenyx Pharmaceuticals.
The Centers for Medicare and Medicaid Services (CMS) recently announced significant changes to evaluation and management coding and documentation requirements.
Patients with radioactive iodine-refractory thyroid cancer (RAIR-DTC) have poor prognoses and, until recently, there were no effective targeted systemic therapies available for RAIR-DTC.